Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 11/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.48 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.48 |
| ▸ | CDC7 | O00311 | 1/20 | 0.47 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425233 | 0.89 | HTT (0.65) | HTTRAB9AKMT2ANPC1NCOA3 | |
| SCHEMBL3177294 | 0.85 | MAPT (0.62) | HTTRAB9AKMT2ANPC1NCOA3 | |
| SCHEMBL14955057 | 0.84 | RAB9A (0.51) | HTTRAB9AKMT2ANPC1NCOA3 | |
| SCHEMBL14955139 | 0.83 | CHRM4 (0.68) | HTTRAB9AKMT2ANPC1NCOA3 | |
| SCHEMBL13392971 | 0.83 | HTT (0.47) | HTTRAB9AKMT2ANPC1NCOA3 | |
| SCHEMBL3176192 | 0.82 | ALDH1A1 (0.51) | HTTRAB9AKMT2ANPC1NCOA3 | |
| SCHEMBL3171779 | 0.81 | CHRM4 (0.53) | HTTRAB9AKMT2ANPC1NCOA3 | |
| SCHEMBL3166637 | 0.80 | MAPT (0.44) | HTTRAB9AKMT2ANPC1NCOA3 | |
| SCHEMBL28973940 | 0.79 | CHRM4 (0.70) | CHRM4MAPTTP53CHRM2CHRM1 | |
| SCHEMBL21048217 | 0.74 | MAPT (0.50) | HTTRAB9AKMT2ANPC1CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100099672-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099672-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-20100099672-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-04-22 | — | — | US | disclosed |
| US-7645881-B2 | Such as tert-Butyl 3-amino-5-ethyl-4,6-dimethylthieno[2,3-B]pyridine-2-carboxylate which inhibits replication | PTC THERAPEUTICS, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1781289-A1 | THIENOPYRIDINES FOR TREATING HEPATITIS C | PTC Therapeutics, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006019832-A1 | THIENOPYRIDINES FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2006-02-23 | — | — | WO | disclosed |
| US-20060019976-A1 | Such as tert-Butyl 3-amino-5-ethyl-4,6-dimethylthieno[2,3-B]pyridine-2-carboxylate which inhibits replication | PTC THERAPEUTICS, INC. | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099672-A1 | METHODS FOR TREATING HEPATITIS C | OAT, HAVCR2, HCCS | HTT 3303/4885RAB9A 3935/4885KMT2A 4029/4885 |
| US-20060019976-A1 | Such as tert-Butyl 3-amino-5-ethyl-4,6-dimethylthieno[2,3-B]pyridine-2-carboxylate which inhibits replication | DIMT1, EIF2AK2, ELL | HTT 3639/4885RAB9A 3380/4885KMT2A 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.